Alivus Life SciencesNSE:ALIVUS -0.70%83 Net Margin % is 23.60% as of Mar. 2026, which is 11% above its 10-year median of 21.23. GuruFocus rates NSE:ALIVUS with a GF Score™ of 83/100 and a GF Value™ of ₹1,004.54 (Fairly Valued). The stock has 3 warning signs investors should review. Among 956 Drug Manufacturers companies, Alivus Life Sciences ranks better than 89.85% on this metric.
The historical rank and industry rank for Alivus Life Sciences's Net Margin % or its related term are showing as below:
NSE:ALIVUS'
s Net Margin % Range Over the Past 10 Years
Min: 18.89 Med: 21.23 Max: 22.8
Current: 22.12
NSE:ALIVUS's Net Margin % is ranked better than 89.85% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs NSE:ALIVUS: 22.12
Alivus Life Sciences (NSE:ALIVUS) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Alivus Life Sciences Net Margin % Related Terms
Alivus Life Sciences Net Margin % Historical Data
* Premium members only.
The historical data trend for Alivus Life Sciences's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Alivus Life Sciences's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alivus Life Sciences Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alivus Life Sciences's Net Margin % distribution charts can be found below:
* The bar in red indicates where Alivus Life Sciences's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alivus Life Sciences (NSE:ALIVUS) has a Net Margin % of 23.60% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Alivus Life Sciences and its competitors. This is 11% above median its historical median of 21.23. Over the past decade, Alivus Life Sciences' Net Margin % has ranged from 18.89 to 22.80. According to the industry distribution chart, Alivus Life Sciences ranks #97 out of 956 companies in the Drug Manufacturers industry, placing it in the top 10.1%.
Is Alivus Life Sciences' Net Margin % too high?
Alivus Life Sciences' current Net Margin % of 23.60% is 11% above median its 10-year median of 21.23. Over the past 10 years, this metric has ranged from a low of 18.89 to a high of 22.80. The Drug Manufacturers industry median Net Margin % is 5.56. Alivus Life Sciences' value of 23.60% is 324.5% above this industry median. Based on the distribution chart, Alivus Life Sciences ranks #97 out of 956 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Alivus Life Sciences has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Alivus Life Sciences' Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Alivus Life Sciences ranks #97 out of 956 companies for Net Margin %. This places Alivus Life Sciences in the top 10% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.56. Alivus Life Sciences' value of 23.60% is 324.5% above this benchmark. Historically, Alivus Life Sciences' own Net Margin % has ranged from 18.89 to 22.80 over the past decade. While the company's 10-year median is 21.23 vs. the industry median of 5.56, Alivus Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alivus Life Sciences's current Net Margin % of 23.60% is 324.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Alivus Life Sciences and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alivus Life Sciences's current Net Margin % is 23.60%, which is 11% above median its own 10-year median of 21.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alivus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Alivus Life Sciences (NSE:ALIVUS) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,004.54, compared to a current price of ₹1,108.30 — trading 10.3% above its estimated fair value. The current Net Margin % is 23.60%, which is 11% above median its 10-year median of 21.23 and 324.5% above the Drug Manufacturers industry median of 5.56. Alivus Life Sciences' overall GF Score™ is 83/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Alivus Life Sciences (NSE:ALIVUS), the current Net Margin % is 23.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alivus Life Sciences (NSE:ALIVUS) Overvalued in 2026?
Based on GuruFocus' analysis, Alivus Life Sciences stock appears to be overvalued.
The current stock price of ₹1,108.30 is trading 10.3% above its estimated GF Value™ of ₹1,004.54.
GuruFocus considers Alivus Life Sciences to be Fairly Valued.
Key valuation signals for NSE:ALIVUS:
Net Margin %: 23.60% (11% above median its 10-year median of 21.23)
GF Value™: ₹1,004.54 vs. price of ₹1,108.30 (10.3% above fair value)
Industry Position: 324.5% above the Drug Manufacturers median (#97 of 956)
No single metric tells the full story. See the NSE:ALIVUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alivus Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disorders, pain management, diabetes, urology, gastrointestinal disorders, and other therapeutic areas.
83GF Score
Get the complete analysis for NSE:ALIVUS
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ALIVUS has been successfully added to your 
